Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.35 | 1.94 |
NAV | ₹16.74 | ₹428.09 |
Fund Started | 18 Oct 2021 | 04 Jun 1999 |
Fund Size | ₹230.79 Cr | ₹3628.03 Cr |
Exit Load | Exit load of 1% if redeemed within 12 months. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 31.30% | 34.18% |
3 Year | 18.18% | 22.70% |
5 Year | - | 28.85% |
1 Year
3 Year
5 Year
Equity | 97.91% | 96.55% |
Cash | 1.09% | 3.37% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 15.23% |
Lupin Ltd. | 6.53% |
Divi's Laboratories Ltd. | 5.02% |
Aurobindo Pharma Ltd. | 4.94% |
Suven Pharmaceuticals Ltd. | 4.84% |
Apollo Hospitals Enterprise Ltd. | 4.80% |
Max Healthcare Institute Ltd. | 3.84% |
Torrent Pharmaceuticals Ltd. | 3.53% |
Laurus Labs Ltd. | 3.21% |
Dr. Reddy's Laboratories Ltd. | 2.93% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.00% |
Max Healthcare Institute Ltd. | 6.22% |
Divi's Laboratories Ltd. | 6.05% |
Cipla Ltd. | 5.90% |
Lupin Ltd. | 5.19% |
Lonza Group Ag | 4.16% |
Mankind Pharma Ltd. | 4.15% |
Poly Medicure Ltd. | 3.60% |
Krishna Institute of Medical Sciences Ltd | 3.46% |
Jupiter Life Line Hospitals Ltd. | 3.45% |
Name | Dhimant Shah | Tanmaya Desai |
Start Date | 01 Dec 2022 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 18 Oct 2021 | 04 Jun 1999 |
Description
Launch Date